<DOC>
	<DOCNO>NCT02088502</DOCNO>
	<brief_summary>The aim study determine efficacy Theophylline , N-Acetylcysteine , Theophylline plus N-acetylcysteine prevention contrast-induced nephropathy . Investigators assume Theophylline plus N-acetylcysteine effective Theophylline alone N-acetylcysteine alone . Investigators include patient refer elective coronary angiography angioplasty allocate mention treatment 24 hour 48 hour administration contrast material . Investigators measure serum creatinine see raise ≥ 0.5 mg/dL ≥ 25 % baseline value .</brief_summary>
	<brief_title>Theophylline , N-acetylcysteine , Theophylline Plus N-acetylcysteine Preventing Contrast-induced Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Acetylcysteine</mesh_term>
	<mesh_term>N-monoacetylcystine</mesh_term>
	<mesh_term>Theophylline</mesh_term>
	<criteria>adult patient candidate elective coronary angiography angioplasty least moderate risk contrast induce nephropathy unstable angina myocardial infarction , cardiac arrhythmia , seizure , acute renal failure , endstage renal disease unstable serum creatinine unstable hemodynamic intravascular administration contrast material past month use theophylline Nacetylcysteine past month , know hypersensitivity theophylline Nacetylcysteine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Coronary Angiography</keyword>
	<keyword>Side Effects</keyword>
	<keyword>Contrast-Induced Nephropathy</keyword>
	<keyword>Prevention</keyword>
</DOC>